NBDF funds a broad range of research programs that seek to increase our understanding of the science behind bleeding disorders, how they affect people's lives, and pathways to better treatments and cures.
Platelet Mechanism Regulating Thrombin Generation
Per Dr. Kempton, the JGP assisted her in determining the direction of her future research. As a result of her JGP project, Dr. Kempton was published in ATVB and published several abstracts.
Depletion of Immune Response to AAV-F.IX
Purification and Characterization of Vitamin K Epoxide Reductase
Development of Self-Complimentary (SC) Adeno-Associated Virus Type 5 (AAV-5) Vectors for Gene Therapy of Hemophilia B
Structure of Factor VIII’s C Domains and their Epitopes
Double-stranded Adeno-associated Virus (dsAAV) Vectors to Improve Efficacy and to Evaluate Safety of Factor IX Gene Therapy
Paul Monahan is Translational and Clinical Development Lead for Hematology Gene Therapy at Spark Therapeutics. Prior to 2015, Dr. Monahan was Professor of Pediatrics, Hematology/Oncology at the University of North Carolina at Chapel Hill, where he spent more than 20 years as an Investigator in the UNC Gene Therapy Center and treating children with bleeding disorders as an Attending Physician in the Harold Roberts Hemophilia Diagnostic and Treatment Center. He served on several clinical medical and scientific foundations and committees including the Board of Directors of the Hemostasis and Thrombosis Research Society. For ten years he served on the Medical and Scientific Advisory Committee of the National Hemophilia Foundation and as the Region IV Director for the US Hemophilia Treatment Center Network (CDC and MCHB). His basic science laboratory maintained a research focus on gene therapy for hemophilia as well as animal models for the study of hemophilic bone and joint disease, inhibitors in hemophilia B, and novel therapies from 1996 through 2016. In 2013 the National Hemophilia Foundation awarded Monahan the NHF Leadership in Research Award. Prior to joining Spark in Spring 2018, he performed preclinical research development and coordinated clinical trial initiation of hemophilia B and hemophilia A gene therapy trials in a collaborative partnership with Asklepios Biopharmaceuticals and as Medical Lead at Baxalta/Shire.
Establishing the Factors Responsible for Hepatocyte Permissiveness to AAV Vectors
Function of Coagulation Factor V in Plasma and Platelet Pools
Development of a Novel Genomic Transfer Approach for the Treatment of Hemophilia Based on Transduction of Adipose Tissue Using Replication-Defective HSV-1 Vectors
Non-primate Lentiviral Vector-Based Gene Therapy for Hemophilia A
Nonviral Gene Delivery for Hemophilia
Gene Transfer of Factor VIII to the Liver in Vivo
Identification of Complement-Type Repeats of LRP Responsible for Interaction with A2 Domain of Factor VIII
Exploiting Mouse Models to Elucidate the Cellular and Molecular Mechanisms Involved in the Pathogenesis of Platelet Storage Pool Deficiencies
Gene Therapy for Hemophilia B by Direct Intramuscular Injections of Recombinant Adeno Associated Virus Serotype Vectors
Development of Improved Adenoviral Vectors Lacking All Adenoviral Coding Sequences for Hemophilia Gene Therapy
Molecular Mechanisms of Combined Factors V and VIII Deficiency
Study of Interactive Sites of Factor VIIIa with Factor IXa
